A Clinical Study Evaluating the Use of 

_ _ _ Zeolite in the Treatment of

Autism Spectrum Disorder

Primary Investigator:  Dr. Seshagiri Rao

Site:  Plano, Texas

Co-Primary Investigator: Dr. Stephanie Cave

Site: Baton rouge, Louisiana

Coordinator: Forrist Lytehaause

Study Duration: Rolling enrollment. 90 days or 180 days if participant receives placebo during Phase 1.
Summary: The study will measure obeservational changes in the participants using the Autism Diagnostic Observational Schedule (ADOS), Pervasive Developmental Disorder Behavioural Inventory (PDDBI) and Autism Treatment Evaluation checklist (ATEC).  Additionally a subgroup will have a series of 9 heavy metal urine excretion tests completed.

Methodology: A clinical psychologist will establish a diagnosis using the ADOS,  participant's parent will complete the PDDBI and ATEC, and a third party with regular contact with the participant such as a teacher or speech theropist may complete the PDDBI:

• Initial baseline 
• At end of Phase 1 - 90 days
• At end of Phase 2 - 180 days (those who received the placebo during Phase 1, receive the liquid zeolite during Phase 2)

Participants:  80 - a portion from Dr. Rao's and Dr. Cave's existing practice and a portion from elsewhere in the USA who will work with Dr. Rao via telephone. For Inclusion and Exclusion criteria click here.

Participant qualification:

• Approval of primary investigator
• Complete evaluation forms as directed by study parameters
• Up to 180 day commitment to make no changes in current protocol.
• Participation is voluntary. Participant may withdraw from study at any time by providing written request.
• Liquid zeolite and study tests are provided to the subjects at no charge.

If you are interested submitting information, check here.

On behalf of Dr. Rao, Dr. Cave and all of the study staff, thank you for your interest and support of this vitally important research.

Forrist T. Lytehaause
Study Coordinator
(719)635-2000
Coordinator (at) ZeoliteAutismStudy.com